Tag Archives: AMPH

A Director at Amphastar Pharmaceuticals is Exercising Options

Today, a Director at Amphastar Pharmaceuticals, Richard Prins, exercised options of Amphastar Pharmaceuticals for $330.3K. Following Richard Prins’ last AMPH Sell transaction on August 16, 2017, the stock climbed by 4.9%. This is Prins’ first transaction since reporting a Sell

Piper Jaffray Believes Amphastar Pharmaceuticals (NASDAQ: AMPH) Still Has Room to Grow

Piper Jaffray analyst David Amsellem reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH) yesterday and set a price target of $26. The company’s shares closed yesterday at $18.92, close to its 52-week high of $19.95. According to TipRanks.com, Amsellem

What Did This CEO Just Do with Personal Shares of Amphastar Pharmaceuticals (NASDAQ: AMPH)?

Yesterday, the CEO & Chief Scientific Officer of Amphastar Pharmaceuticals (NASDAQ: AMPH), Jack Zhang, sold shares of AMPH for $6.09M. Following Jack Zhang’s last AMPH Sell transaction on September 15, 2017, the stock climbed by 2.0%. The company has a

Jefferies Remains a Buy on Amphastar Pharmaceuticals

Jefferies analyst David Steinberg reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH) on October 27 and set a price target of $19. The company’s shares closed on Friday at $18.41. According to TipRanks.com, Steinberg is a 3-star analyst with

Amphastar Pharmaceuticals Gets a Buy Rating from Piper Jaffray

In a report issued on October 20, David Amsellem from Piper Jaffray reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), with a price target of $19. The company’s shares closed on Friday at $18.50. According to TipRanks.com, Amsellem is

Amphastar Pharmaceuticals Receives a Buy from Piper Jaffray

In a report issued on September 15, David Amsellem from Piper Jaffray reiterated a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), with a price target of $19. The company’s shares closed on Friday at $15.73. According to TipRanks.com, Amsellem is